NoneNo Change
All-cause mortality
Semaglutide → All-cause mortality
Semaglutide → All-cause mortality
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Semaglutide improves cardiorenal outcomes in high-risk diabetes patients
Key finding
Semaglutide significantly reduced the risk of primary MACE (HR [95% CI] 0.76 [0.62; 0.92], p = 0.0062).
This study evaluated the cardiorenal effects of semaglutide in individuals with type 2 diabetes at high cardiovascular risk, finding significant reductions in major adverse cardiovascular events.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Long-Term (1–5 y)
High bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Semaglutide
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Primary outcome
Time to primary major adverse MACE
Comparator
Placebo
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the cardiorenal effects of semaglutide in individuals with type 2 diabetes at high cardiovascular risk, finding significant reductions in major adverse cardiovascular events.
Clinical relevance
These findings are important as they suggest that semaglutide may be an effective treatment option for reducing cardiovascular risks in patients with type 2 diabetes, a population that is often at elevated risk for heart complications. This could lead to improved management strategies for these patients, potentially reducing the burden of cardiovascular disease.
Keep in mind
The study did not show significant effects on cardiovascular death or all-cause mortality. The generalizability of findings may be limited to the specific population studied. Potential confounding factors were not fully explored.
Published in
Journal Reference
Publication details and source links for this paper.
Jingmin Z, Mansoor H, Yang L, et al. Cardiorenal effects of semaglutide in people with type 2 diabetes at high cardiovascular risk. Diabetes, Obesity & Metabolism. 2025;27(10):5706-5715. doi:10.1111/dom.16621
Save this study and add notes to your research library.
Main Effects
Semaglutide significantly reduced the risk of primary MACE (HR 0.76, p = 0.0062).
Semaglutide significantly reduced the risk of expanded MACE (HR 0.80, p = 0.0097).
Semaglutide consistently reduced nephropathy risk (HR 0.64, p = 0.0054).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide and All-cause mortality, Cardiovascular death, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), and 1 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- All-cause mortality
- Cardiovascular death
- Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
4
Evidence pairs
75
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
NoneNo Change
Cardiovascular death
Semaglutide → Cardiovascular death
Semaglutide → Cardiovascular death
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
StrongDecrease
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
StrongDecrease
Nephropathy progression
Semaglutide → Nephropathy progression
Semaglutide → Nephropathy progression
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Semaglutide reduced the risk of primary MACE by 24%.
- Expanded MACE risk decreased by 20% with semaglutide.
- Nephropathy risk was reduced by 36%.
Who this applies to
- Adults with type 2 diabetes.
- Individuals at high cardiovascular risk.
Keep in Mind
- Results may not apply to all diabetes populations.
- Further studies are needed to confirm long-term effects.
- The study did not assess the impact on quality of life.
Between the Lines
- The study did not show significant effects on cardiovascular death or all-cause mortality.
- The generalizability of findings may be limited to the specific population studied.
- Potential confounding factors were not fully explored.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Cardiovascular Outcomes, GLP-1 Receptor Agonists and Cardiovascular Outcomes.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Cardiovascular Outcomes Evidence Hub
All studies measuring Cardiovascular Outcomes
5 studies
outcome_hubMeasures Cardiovascular Outcomes as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
5 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Semaglutide and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Intervention: SemaglutideOutcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
5 results
All studies on Semaglutide and All-cause mortality
Intervention: SemaglutideOutcome: All-cause mortality
6 results
All studies on Semaglutide
Intervention: Semaglutide
5 results
All studies measuring Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Outcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
5 results
All studies measuring All-cause mortality
Outcome: All-cause mortality
6 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve cardiovascular outcomes?
Emerging Evidence
GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.
ConsensusScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Emerging | EvidenceScore™ 57.7 | moderate positive | ConsensusScore™ Generally Consistent | 1 study
- 2
All-cause mortality
EvidenceScore™ Emerging | EvidenceScore™ 54.4 | weak positive | ConsensusScore™ Mixed | 1 study
Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve kidney function?
Limited Evidence
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Kidney Function.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Nephropathy progression
EvidenceScore™ Emerging | EvidenceScore™ 49.1 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Semaglutide improve cardiovascular death?
Limited Evidence
Semaglutide may worsen Cardiovascular death or be associated with harm.
ConsensusScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Cardiovascular death
EvidenceScore™ Limited | EvidenceScore™ 31.4 | weak negative | ConsensusScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.